Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
58 hedge funds and large institutions have $95M invested in Odonate Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 27 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less funds holding
Funds holding: 69 → 58 (-11)
17% less capital invested
Capital invested by funds: $114M → $95M (-$19M)
34% less call options, than puts
Call options by funds: $150K | Put options by funds: $228K
56% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 27
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.63M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$972K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$340K |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
+$299K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$209K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.63M |
| 2 |
Two Sigma Advisers
New York
|
-$1.51M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.19M |
| 4 |
Two Sigma Investments
New York
|
-$1.17M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.14M |
ODT Hedge Fund Activity: Q3 2021 in Review
58 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q3 2021, worth a combined $95M — down 17% from $114M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ODT and 6 opened new positions — a net loss of 11 holders — while 27 trimmed existing stakes and 12 added.
The largest buyer was EcoR1 Capital, adding an estimated $9.63M. The largest seller was Morgan Stanley, cutting an estimated $2.63M.
- 58 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q3 2021, down from 69 in Q2 2021.
- Funds reported $95M of Odonate Therapeutics, Inc. Common Stock stock for Q3 2021, down 17% quarter-over-quarter.
- 6 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q3 2021 and 17 closed out, a net change of -11 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q3 2021 was EcoR1 Capital, an estimated $9.63M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q3 2021 was Morgan Stanley, an estimated $2.63M sold.
Based on aggregated 13F filings for Q3 2021.